AzTrials
AzTrials

HyperparathyroidismNCT00513032

Interaction Between Anaesthetics and Methylene Blue

An observational study of Hyperparathyroidism, run by University Hospital, Geneva at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

We hypothesized that pre-treatment with methylene blue could potentiate the effects of general anaesthetic agents in patients undergoing parathyroidectomy Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hyperparathyroidism
What is being tested?
methylene blue
Type of treatment
Injection or infusion
How many people
22 participants
Where
1 siteSwitzerland
Study dates
Jan 2005to Apr 2007
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients undergoing parathyroidectomy or partial thyroidectomy

Who cannot join

  • Psychiatric disorders
  • Drug abuse
  • Weight 20% more or less than ideal body weight

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Service d'Anesthésiologie, Hôpitaux Universitaires de Genève, Rue Micheli-du-Crest

    Geneva, CH-1211

Other trials in Switzerland

About this study

Official title: Effects of Methylene Blue on Propofol Requirement During Anaesthesia Induction and Surgery

We hypothesized that pre-treatment with methylene blue could potentiate the effects of general anaesthetic agents in patients undergoing parathyroidectomy

Read the detailed description

Sample and study design The local ethics committee granted approval for this study and informed written consent will be obtained from all participants. We will study ASA grade I or II patients, aged between 45 and 73 years who were free from cardiovascular and pulmonary diseases. Patients with psychiatric disorders or drug abuse as well as those weighing 20% more or less than their ideal body weight will all be excluded.

The interventional group will consist of 11 patients scheduled for elective parathyroidectomy who will receive MB infusion (5mg.kg-1 in 250 ml 5% glucose-saline) approximately 60 min before anaesthesia induction. A further 11 patients scheduled for unilateral thyroid lobectomy without MB pre-treatment will be recruited as controls. They will present with normal thyroid tests and will carefully be selected in an attempt to match the intervention group on the basis of age, weight and sex. Both types of surgical procedures will be performed by the same surgical team.

Anaesthesia and surgery All patients will be premedicated with oral midazolam 7.5 mg and they will receive a loading dose of lactate-ringer solution (5 ml.kg-1) intravenously after arrival in the operating theatre. The standard anaesthetic monitoring will comprise non-invasive blood pressure, ECG, pulsed oxygen saturation and end-tidal carbon dioxide. Processed EEG parameters will be acquired with a BIS monitor, using surface electrodes, with impedance maintained at less than 5kΩ to ensure adequate signal quality. Raw EEG data from two channels (F7-CZ and F8-CZ) will be processed by company proprietary software and the BIS values (calculated for each 4-sec epoch) will be continuously displayed along with the trend line.

Propofol will be infused using a commercially available TCI system loaded with Schneider's 3-compartment pharmacokinetic model wherein the individual patient's age, height and weight will be programmed. The target effect-site concentration of propofol will be computed to yield a time to peak effect of 1.6 min, which has been confirmed clinically.

During anaesthesia induction, the patients will breath an air-oxygen mixture through a face mask. The target effect-site concentration of propofol will first be set at 0.5 ng.ml-1 and it will be increased by 0.2 ng.ml-1 every 2 min until the clinical endpoint will be achieved (loss of consciousness and unresponsiveness). Then, ventilation will be assisted manually and the trachea will be intubated after the intravenous administration of fentanyl (100 mcg) and rocuronium (0.7 mg.kg-1).

During anaesthesia maintenance, the effect-site concentration of propofol will be targeted to achieve BIS values between 30 and 60. Additional fentanyl, rocuronium or vasopressor agents (ephedrine) will be given at the discretion of the attending anaesthetist.

Measurements When each patient will be comfortable on the operating table, baseline measurements of BIS, mean arterial pressure (MAP), heart rate (HR) and pulsed oxygen saturation (SpO2) will be taken.

During propofol induction, BIS values, MAP, HR and SpO2 will be recorded every 1-min and the Observer's Assessment of Alertness/Sedation (OAAS) rating scale will be recorded after each equilibration period (score 5=awake and responds readily to name spoken in normal tone; 4= lethargic response to name in normal tone; 3=response only after name is called loudly and/or repeatedly; 2= response only after name is called loudly and after mild shaking; 1= dose not respond when name is called and after mild shaking).

During surgery and anaesthesia maintenance, BIS values and the effect-site concentration of propofol will be recorded each 5-min.

Other recorded data will include the doses of propofol required for anaesthesia induction and maintenance, the total amount of vasopressor and the time until anaesthesia emergence and readiness for tracheal extubation.

Statistics Assuming that MB pre-treatment would reduce the requirement of propofol by 25%, power analysis with alpha = 0.05, beta = 0.8, shows that we would need to study at least 10 patients in each group. The computer program SAS 8.0 for Windows will be used for all data analyses. Parametric data will be analysed by two-way ANOVA. Unpaired Student t-tests, Chi-squared tests and Fisher's exact probability tests will be used as appropriate for comparison between groups. All values are expressed as mean (M), standard deviation (SD) and statistical significance will be accepted at p < 0.05.

Being tested
methylene blue
Keywords
propofol, anaesthesia induction, parathyroidectomy, methylene blue, General anesthesia
Medical subject headings
Hyperparathyroidism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • methylene blueDrug

    5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction

Study groups in NCT00513032
Study groupRoleWhat they receive
methylene blueNot described
Receives: Drug: methylene blue
CNot described
Receives: Drug: methylene blue

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2007 (estimated)
  2. Study startJan 2005
  3. Study completionApr 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
22 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00513032
Sponsor's protocol ID
02-081(02-006)
Status last verified
Aug 2007
First submitted
7 Aug 2007
Last updated
8 Aug 2007
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Hyperparathyroidism, run by University Hospital, Geneva at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Aug 2007. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Aug 2007.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in